K2 HealthVentures (K2HV) has launched a new specialty finance firm that will provide long-term debt, equity, and intellectual capital to private and public life sciences and healthcare companies.
With $400M initial capital commitment, which is expected to grow significantly over time, the firm will initially target investments ranging in size from $10-50m.
K2HV’s primary focus will be on customized debt financing, enabling innovative companies to minimize equity dilution as they reach key lifecycle milestones and build enterprise value. In addition, the firm also has the ability to invest equity capital, thereby aligning its long-term interests with those of its venture and public equity investment partners.
A key principle of K2HV’s charter is its commitment to devoting a portion of investment profits to fund underserved and underinvested areas in the healthcare space, both in the US and globally.
With offices in Boston and New York, the K2HV investment team led by Parag Shah, Founding Managing Director and CEO, brings together a combination of debt and equity investment expertise, industry experience, and domain knowledge, along with a deep understanding of the needs of innovative life sciences and healthcare companies throughout their lifecycles.
K2 HealthVentures is backed by L1 Health, an international investment firm with extensive experience in healthcare.